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Background: It is currently not possible to get an approval of our ethics committee for a randomized trial
cmparing 5x4 Gy and 10x3 Gy for MSCC that includes patients with favorable survival prognoses. Therefore, this
matched-pair study following strict matching criteria was perfomed instead.
Methods: In this study, 142 receiving 5x4 Gy were retrospectively matched (1:1) to 142 patients receiving 10x3 Gy
with respect to ten characteristics. These characteristics included age, gender, performance status, tumor type,
involved vertebrae, other bone metastases, visceral metastases, interval between tumor diagnosis and MSCC, pre-RT
ambulatory status, and time developing motor deficits.
Results: On multivariate analysis, post-RT motor function was associated with performance status (p < 0.001), tumor
type (p < 0.001), and time developing motor deficits (p < 0.001). RT was successful in 76% of patients receiving 5x4 Gy
and 69% receiving 10x3 Gy (p = 0.14). Pre.RT ambulatory status showed a strong trend with respect to local control (LC)
of MSCC in the multivariate analysis (p = 0.058). 1-year LC rates were 87% after 5x4 Gy and 93% after 10x3 Gy (p = 0.16).
On multivariate analysis, survival (OS) was associated with performance score (p < 0.001), visceral metastases (p < 0.001),
and pre-RT ambulatory status (p = 0.004). 1-year OS rates were 68% after 5x4 Gy and 73% after 10x3 Gy (p = 0.64).
Conclusions: In patients irradiated for MSCC who had favorable survival prognoses, post-RT motor function, LC and OS
were not significantly different after 5x4 Gy and after 10x3 Gy.
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Treatment outcomesBackground
Five to 10% of adult cancer patients experience meta-
static spinal cord compression (MSCC) during the
course of their malignant disease, which is considered an
oncologic emergency [1,2]. The vast majority of these
patients receive radiotherapy (RT), either alone or pre-
ceded by decompressive surgery. Carefully selected pa-
tients can benefit from the addition of surgery, whereas
most patients worldwide presenting with MSCC are* Correspondence: rades.dirk@gmx.net
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unless otherwise stated.treated with RT alone [3]. Such a palliative situation like
MSCC requires an individualized treatment approach,
including the most appropriate fractionation schedule of
RT. A variety of fractionation schedules are in use for
MSCC ranging from single-fraction RT to fractionated
schedules given over weeks. For example, RT with a
short overall treatment time would be ideal for patients
with a poor estimated survival time, if it was as effective
as more time consuming schedules.
Until now, only three randomized trials exist that
compared different fractionation schedules for MSCC.
Two studies compared two fractions of 8 Gy (with one
week rest between the two fractions) to either a split-This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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5x3 Gy given over one week) or 1x8 Gy [4,5]. In both of
these trials, the compared fractionation schedules re-
sulted in similar treatment outcomes. The most fre-
quently used fractionation schedules for MSCC are 5x4
Gy over one week and 10x3 Gy over two weeks. There-
fore, it appears reasonable to compare these schedules in
a randomized trial. Such a trial was begun and prelimin-
ary results presented last year at the annual ESTRO
meeting [6]. Due to ethical considerations this trial was
limited to patients with a poor or intermediate survival
prognosis, since retrospective studies suggested that pa-
tients with more favorable survival prognoses benefit
from longer-course RT such as 10x3 Gy in terms of bet-
ter local control of MSCC. However, such retrospective
studies always bear the risk of selection bias. Patients
considered to have a more favorable survival prognosis
may have received preferentially 10x3 Gy rather than 5x4
Gy. Nevertheless, the results of the retrospective studies
shouldn’t be ignored. Therefore, it is currently not possible
to get an approval of our ethics committee for a random-
ized trial comparing 5x4 Gy and 10x3 Gy for MSCC that
includes patients with more favorable survival prognoses.
Because further studies defining the optimal fractionation
schedule of RT for MSCC in patients with a more favorable
prognosis are required, we performed a matched-pair study
with strict matching criteria in an attempt to minimize the
inclusion of biases.
Patients and methods
In this matched-pair study, two fractionation schedules
were compared in patients with MSCC and more favor-
able survival prognoses. The patients had a score of
more than 35 points in a validated survival score [7,8].
That score considered six prognostic factors found to be
significantly associated with OS in a multivariate ana-
lysis. These factors included the type of primary tumor,
other bone metastases at the time of RT, visceral metas-
tases at the time of RT, interval between tumor diagnosis
and MSCC, ambulatory status prior to RT, and time de-
veloping motor deficits prior to RT. The score for each
factor was obtained from the 6-month survival rates di-
vided by 10. The survival score for each patient repre-
sented the sum of the six factor scores and ranged from
20 to 45 points. In the simplified version of the scoring
system, three prognostic groups were defined: 20–30
points (poor survival prognosis), 31–35 points (inter-
mediate survival prognosis), and 36–45 points (more
favorable survival prognosis).
The present study was approved by the local ethic
committee (University of Lübeck). We retrospectively
matched (1:1) 142 patients receiving 5x4 Gy in one
week to 142 patients receiving 10x3 Gy in two weeks
with respect to ten patient characteristics. The tencharacteristics included age (≤63 versus ≥ 64 years,
median age: 63.5 years), gender, Eastern Cooperative
Oncology Group (ECOG) performance status (1–2
versus 3–4), type of primary tumor (breast cancer ver-
sus prostate cancer versus myeloma/lymphoma versus
lung cancer versus other tumors), number of involved
vertebrae (1–2 versus ≥ 3), other bone metastases at
the time of RT (no versus yes), visceral metastases at
the time of RT (no versus yes), interval between tumor
diagnosis and MSCC (≤15 months versus >15 months),
ambulatory status prior to RT (not ambulatory versus
ambulatory), and time developing motor deficits prior
to RT (1–7 versus 8–14 versus >14 days). The distri-
butions of the patient characteristics are summarized
in Table 1.
Further criteria for inclusion were MSCC of the thor-
acic or lumbar spine, no prior surgery or RT to the
spinal regions involved by MSCC, and confirmation of
MSCC by spinal computed tomography or spinal mag-
netic resonance imaging. RT was performed with linear
accelerators to the spinal segments involved by MSCC
plus one normal vertebra above and below the meta-
static lesions. If the spinal lesions extended to the cer-
vical spine, two normal vertebrae above the metastatic
lesions were included.
The grading of each patient’s motor function was per-
formed with a 5-point scale [9]: Grade 0: normal
strength; Grade 1: ambulatory without aid, Grade 2: am-
bulatory with aid, Grade 3: not ambulatory, Grade 4:
paraplegia. The ambulatory status has been routinely
assessed in the centers participating in this study. Im-
provement or deterioration of motor function was de-
fined as a change of at least one point. The fractionation
schedule and the ten additional patient characteristics
were analyzed with respect to the success of RT. Suc-
cessful RT was defined either as improvement of motor
function by at least one point or as maintaining the sta-
tus “ambulatory without aid”. The investigated 11 factors
were evaluated in a multivariate manner with a logistic
regression analysis.
LC was defined as freedom from an in-field recur-
rence of MSCC in the irradiated spinal segments. An
in-field recurrence had to be confirmed by spinal im-
aging. LC and OS rates were counted from the last day
of RT. For the univariate analyses of LC and OS, the
Kaplan-Meier-method [10] and the log-rank test were
used. The characteristics identified as significant
(p < 0.05) on univariate analysis were subsequently an-
alyzed in a multivariate manner with the Cox propor-
tional hazards model. If applicable, two separate analyses
were performed including either ambulatory status or
ECOG performance status, since both are confounding
variables. The patients were followed until death or for
Table 1 Distribution of the potential prognostic factors in
the two treatment groups
5 x 4 Gy 10 x 3 Gy
N patients (%) N patients (%)
Age
≤63 years (N = 142) 71 (50) 71 (50)
≥64 years (N = 142) 71 (50) 71 (50)
Gender
Female (N = 138) 69 (49) 69 (49)
Male (N = 146) 73 (51) 73 (51)
ECOG performance status
1-2 (N = 226) 113 (80) 113 (80)
3-4 (N = 58) 29 (20) 29 (20)
Type of primary tumor
Breast cancer (N = 110) 55 (39) 55 (39)
Prostate cancer (N = 76) 38 (27) 38 (27)
Myeloma/lymphoma (N = 40) 20 (14) 20 (14)
Lung cancer (N = 12) 6 (4) 6 (4)
Other tumors (N = 46) 23 (16) 23 (16)
Involved vertebrae (N)
1-2 (N = 134) 67 (47) 67 (47)
≥3 (N = 150) 75 (53) 75 (53)
Other bone metastases at
the time of RT
No (N = 140) 70 (49) 70 (49)
Yes (N = 144) 72 (51) 72 (51)
Visceral metastases at the time
of RT
No (N = 264) 132 (93) 132 (93)
Yes (N = 20) 10 (7) 10 (7)
Interval from tumor diagnosis to
MESCC
≤15 months (N = 80) 40 (28) 40 (28)
>15 months (N = 204) 102 (72) 102 (72)
Ambulatory status before RT
Not ambulatory (N = 30) 15 (11) 15 (11)
Ambulatory (N = 254) 127 (89) 127 (89)
Time developing motor deficits
before RT
1-7 days (N = 20) 10 (7) 10 (7)
8-14 days (N = 68) 34 (24) 34 (24)
>14 days (N = 196) 98 (69) 98 (69)
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at the last follow-up.
Results
According to the multivariate analysis, the effect of RT
on motor function was significantly associated with theECOG performance status (p < 0.001), the type of pri-
mary tumor (p < 0.001), and the time developing motor
deficits prior to RT (p < 0.001). The success of RT with re-
spect to motor function was not significantly associated
with the fractionation schedule of RT (p = 0.14). RT was
successful in 76% of patients receiving 5x4 Gy and in 69%
of patients receiving 10x3 Gy, respectively. The results of
the analysis of the RT effect on motor function are sum-
marized in Table 2.
Pre-RT ambulatory status was significantly associated
with LC of MSCC in the univariate analysis (p = 0.027)
and showed a strong trend in the multivariate analysis
(p = 0.058). The time of developing motor deficits prior
to RT was significant in the univariate analysis of LC
(p = 0.028) but not in the multivariate analysis
(p = 0.60). The fractionation schedule had no significant
association with LC (p = 0.16). The 1-year LC rates were
87% after 5x4 Gy and 93% after 10x3 Gy, respectively.
The results of the univariate analysis of LC of MSCC
are shown in Table 3, and the results of the multivariate
analysis in Table 4.
In the univariate analysis of survival, OS was associ-
ated with ECOG performance status (p < 0.001), visceral
metastases at the time of RT (p < 0.001), and ambulatory
status prior to RT (p = 0.006). The fractionation schedule
had no significant impact on OS (p = 0.64). The 1-year
OS rates were 68% after 5x4 Gy and 73% after 10x3 Gy,
respectively. The results of the univariate analysis of OS
are summarized in Table 5. In the multivariate analysis,
OS was significantly associated with ECOG performance
score (p < 0.001), visceral metastases at the time of RT
(p < 0.001), and ambulatory status prior to RT (p = 0.004).
Results of the multivariate analysis of OS are summarized
in Table 6.
Acute toxicity such as nausea, diarrhea and radiation
dermatitis did not exceed grade 1 according to CTCAE
4.0 in both groups. Late radiation toxicity, particularly
radiation myelopathy, was not observed.
Discussion
MSCC is a palliative situation requiring an individual
treatment approach tailored to each patient’s personal
situation and needs. The vast majority of these patients
do receive RT. One important question is whether the
patient would likely benefit from the addition of decom-
pressive surgery plus stabilization of the involved verte-
brae prior to RT? Ten years ago, a small randomized
trial including 101 patients demonstrated a benefit for
carefully selected patients who had a favorable perform-
ance status, a survival prognosis of at least a few
months, involvement of only one spinal segment by
MSCC, and a solid tumor not considered very radiosen-
sitive [3]. The effect on the patients’ ambulatory status
was better after the combined approach than after RT
Table 3 Impact of potential prognostic factors on local







5 x 4 Gy (N = 142) 95 87
10 x 3 Gy (N = 142) 98 93 0.16
Age
≤63 years (N = 142) 97 92
≥64 years (N = 142) 97 87 0.84
Gender
Female (N = 138) 98 93
Male (N = 146) 95 86 0.27
ECOG performance status
1-2 (N = 226) 97 91
3-4 (N = 58) 96 82 0.11
Type of primary tumor
Breast cancer (N = 110) 99 93
Prostate cancer (N = 76) 95 84
Myeloma/lymphoma (N = 40) 100 95
Lung cancer (N = 12) 100 100
Other tumors (N = 46) 91 84 0.16
Involved vertebrae (N)
1-2 (N = 134) 98 93
≥3 (N = 150) 96 87 0.09
Other bone metastases at the time of RT
No (N = 140) 96 91
Yes (N = 144) 97 88 0.53
Visceral metastases at the time of RT
No (N = 264) 97 90
Yes (N = 20) 100 80 0.32
Interval from tumor diagnosis to MESCC
≤15 months (N = 80) 97 97
>15 months (N = 204) 97 88 0.24
Ambulatory status before RT
Not ambulatory (N = 30) 96 71
Ambulatory (N = 254) 97 91 0.027
Time developing motor deficits before RT
1-7 days (N = 20) 78 78
8-14 days (N = 68) 98 96
>14 days (N = 196) 98 89 0.028







N patients (%) N patients (%)
RT regimen
5 x 4 Gy (N = 142) 108 (76) 34 (24)
10 x 3 Gy (N = 142) 98 (69) 44 (31) 0.14
Age
≤63 years (N = 142) 104 (73) 38 (27)
≥64 years (N = 142) 102 (72) 40 (28) 0.77
Gender
Female (N = 138) 110 (80) 28 (20)
Male (N = 146) 96 (66) 50 (34) 0.51
ECOG performance status
1-2 (N = 226) 177 (78) 49 (22)
3-4 (N = 58) 29 (50) 29 (50) <0.001
Type of primary tumor
Breast cancer (N = 110) 93 (85) 17 (15)
Prostate cancer (N = 76) 51 (67) 25 (33)
Myeloma/lymphoma
(N = 40)
29 (73) 11 (27)
Lung cancer (N = 12) 10 (83) 2 (17)
Other tumors (N = 46) 23 (50) 23 (50) <0.001
Involved vertebrae (N)
1-2 (N = 134) 95 (71) 39 (29)
≥3 (N = 150) 111 (74) 39 (26) 0.49
Other bone metastases at
the time of RT
No (N = 140) 101 (72) 39 (28)
Yes (N = 144) 105 (73) 39 (27) 0.28
Visceral metastases at the
time of RT
No (N = 264) 193 (73) 71 (27)
Yes (N = 20) 13 (65) 7 (35) 0.68
Interval from tumor
diagnosis to MESCC
≤15 months (N = 80) 50 (63) 30 (37)
>15 months (N = 204) 156 (76) 48 (24) 0.12
Ambulatory status before RT
Not ambulatory (N = 30) 18 (60) 12 (40)
Ambulatory (N = 254) 188 (74) 66 (26) 0.47
Time developing motor
deficits before RT
1-7 days (N = 20) 7 (35) 13 (65)
8-14 days (N = 68) 43 (63) 25 (37)
>14 days (N = 196) 156 (80) 40 (20) <0.001
The p-values were obtained from the multivariate analysis.
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57%, respectively (p = 0.001). The median OS times were
4.2 months and 3.3 months, respectively (p = 0.033). Tak-
ing into account the specific selection criteria used for this
trial, only 10-15% of all patients presenting with MSCC
would be suitable candidates for upfront decompressive








5 x 4 Gy (N = 142) 87 68
10 x 3 Gy (N = 142) 84 73 0.64
Age
≤63 years (N = 142) 90 73
≥64 years (N = 142) 81 68 0.29
Gender
Female (N = 138) 87 74
Male (N = 146) 84 67 0.20
ECOG performance status
1-2 (N = 226) 92 77
3-4 (N = 58) 60 43 <0.001
Type of primary tumor
Breast cancer (N = 110) 89 80
Prostate cancer (N = 76) 80 71
Myeloma/lymphoma (N = 40) 78 63
Lung cancer (N = 12) 83 56
Other tumors (N = 46) 93 50 0.11
Involved vertebrae (N)
1-2 (N = 134) 89 69
≥3 (N = 150) 83 71 0.42
Other bone metastases at the time of RT
No (N = 140) 91 72
Yes (N = 144) 80 68 0.10
Visceral metastases at the time of RT
No (N = 264) 88 73
Yes (N = 20) 50 35 <0.001
Interval from tumor diagnosis to MESCC
≤15 months (N = 80) 80 63
>15 months (N = 204) 88 73 0.25
Ambulatory status before RT
Not ambulatory (N = 30) 63 50
Ambulatory (N = 254) 88 73 0.006
Time developing motor deficits
before RT
1-7 days (N = 20) 85 73
8-14 days (N = 68) 79 59
>14 days (N = 196) 88 74 0.23
Table 4 Multivariate analysis of local control of MSCC
Risk ratio 95%-confidence interval P-value
Ambulatory status before radiotherapy 2.88 0.96 – 7.04 0.058
Time of developing motor deficits before radiotherapy 1.19 0.60 – 2.12 0.60
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alone. Although high-precision techniques such as radio-
surgery, SBRT and IMRT become more popular for the
treatment of painful vertebral metastases [11-13], these
techniques are generally not recommended fpr MSCC
outside clinical trials [14,15]. This means that conven-
tional RT is the most common modality used for treating
MSCC.
If conventional RT is administered, the fractionation
schedule should be carefully selected to meet the pa-
tient’s individual situation and prognosis. Fractionation
schedules applied for MSCC include single-fraction,
short-course multi-fraction and longer-course programs.
Several retrospective and prospective studies have shown
that fractionation schedule has no significant impact on
the effect of RT on post-treatment motor function and
ambulatory status. Therefore, at least those patients who
are estimated to have a short remaining life span appear
good candidates for receiving either single-fraction RT
or short-course multi-fraction RT. For better prognosis
patients who are likely to live six months or longer fol-
lowing RT, longer-course programs appear more appro-
priate because two large retrospective studies and a
prospective study (SCORE-1) did suggest a better LC of
MSCC for longer-course RT with 10x3 Gy, 15x2.5 Gy or
20x2 Gy when compared to 1x8 Gy or 5x4 Gy [16-18].
In the SCORE-1 study, the rates of LC of MSCC at one
year were 81% and 61%, respectively (p = 0.005) [18].
However, the SCORE-1 study was not randomized. Fur-
thermore, 1x8 Gy and 5x4 Gy were combined to the
short-course RT group, and 10x3 Gy, 15x2.5 Gy and
20x2 Gy were combined to the longer-course RT group.
The two most frequently used fractionation schedules
for MSCC, 5x4 Gy and 10x3 Gy, have been directly
compared for the first time in a prospective randomized
trial named SCORE-2 [6]. Preliminary results of that
trial were presented at the annual ESTRO meeting last
year. According to these preliminary results, 5x4 Gy and
10x3 Gy were not significantly different with respect to
effect on motor function, post-RT ambulatory status,
pain relief, LC of MSCC and OS. However, the SCORE-
2 trial is limited to patients with a poor or intermediate
survival prognosis based on a validated survival score.
The risk of developing an in-field recurrence of MSCC
increases with the patient’s remaining lifetime. Thus,
patients with favorable survival prognoses are at a
higher risk of developing a recurrence than those pa-
tients with a poor or intermediate survival prognosis.
Table 6 Multivariate analysis of overall survival
Risk ratio 95%-confidence interval P-value
ECOG performance status 2.76 1.69 – 4.39 <0.001
Visceral metastases at the time of radiotherapy 4.47 2.44 – 7.70 <0.001
Ambulatory status before radiotherapy 2.49 1.36 – 4.26 0.004
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short-course than after longer-course RT, patients with
favorable survival prognoses were not included in the
SCORE-2 trial [16-18]. Since a direct comparison of
5x4 Gy and 10x3 Gy is an important issue for all pa-
tients with MSCC, we performed the present matched-
pair study following strict matching criteria in order to
further contribute to answering the question whether
10x3 Gy is really superior to 5x4 Gy, or if both sched-
ules are similarly effective in patients with a favorable
survival prognosis?
According to the results of the present study, 5x4 Gy
and 10x3 Gy were not significantly different with respect
to the effect on post-RT motor function, LC of MSCC
and OS. In other words, 5x4 Gy appeared not inferior to
10x3 Gy in patients with MSCC and favorable survival
prognoses. The results of the present study support per-
forming an additional randomized trial comparing 5x4
Gy and 10x3 Gy that is not strictly limited to patients
with a poor or intermediate survival prognosis but fo-
cuses on patients with longer estimated survival times.
Such a randomized trial is desirable, because the current
study with strict matching criteria is retrospective in na-
ture and may, therefore, include selection biases. How-
ever, since particularly patients with a favorable survival
prognosis may be suitable candidates for upfront decom-
pressive surgery or high-precision RT techniques, the re-
cruitment of such a randomized trial can be exceedingly
difficult [3]. Therefore, we expect that just such a trial
will be very unlikely to be performed in the near future.
Patients with a slower development of motor deficits
prior to RT (>14 days) did respond significantly better to
RT than those patients, in whom motor deficits developed
more rapidly. This can be explained by the fact that a
slower development of (symptomatic) spinal cord compres-
sion results in venous congestion, which is quite likely to be
reversible after treatment with RT. In contrast, a rapid pro-
gression of spinal cord compression can lead to disruption
of the arterial blood flow, which may result in non-
reversible infarction of the spinal cord [19].
Conclusions
The results of 5x4 Gy and 10x3 Gy were not significantly
different in in patients with MSCC and favorable sur-
vival prognoses with respect to post-RT motor function,
LC of MSCC and OS. The results of the present
matched-pair study would justify a randomized trial thatcompares 5x4 Gy and 10x3 Gy for MSCC and focuses
on patients with a longer estimated survival time to de-
velop a higher level of clinical evidence that the shorter
program is optimal.
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